NEWS | BEAM Alliance


BIOASTER, Cynbiose, ICTA, and PharmaLex launch a new hub to support innovative AMR solutions for Biopharma Companies

Pioneering initiative to Fast-Track Antimicrobials from R&D to commercialization

S.O.L.V.E.-AMR- Solutions for Overcoming and Leveraging Versatile Efforts Against Microbial Resistance

LYON – DIJON – PARIS, Tuesday October 10th, 2023

BIOASTER, Cynbiose, ICTA, and PharmaLex announced today a strategic collaboration that aims to help combat antimicrobial resistance (AMR). As part of the initiative, the organizations will leverage their collective expertise and capabilities to offer innovative and integrated support from discovery, pre-clinical and clinical drug development processes up to registration and commercialization, helping to accelerate the development of antimicrobials.

AMR, which occurs when a microorganism (bacteria, viruses, fungi, parasites) develops the ability to resist the effects of a drug, is a significant global public health threat. The World Health Organization (WHO), U.S. Government and European Commission each have initiated action plans against AMR. Boosting research, development and innovation—including developing new therapeutics and alternatives—is a key objective of the EU’s One Health Action Plan against AMR.

The services include regulatory affairs, market access strategies, in-depth risk analyses, nonclinical and clinical R&D services, aiming to support the development and commercialization of novel antimicrobials. This hub will deliver integrated support across the development and commercialization journey, thanks to fit-for-purpose solutions and innovative technologies, including client-driven, stand-alone to end-to-end antimicrobial development services.

“We are proud to collaborate with Cynbiose, ICTA, and PharmaLex in launching this initiative to combat AMR,” said Xavier Morge, CEO of BIOASTER. “Together, we are determined to address this global challenge by providing innovative solutions and accelerating the development of effective antimicrobials. We look forward to working closely with our clients/partners to contribute to providing new treatments adapted to
unmet patient needs.”

Full PR available here